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Abstract
Cognitive effects of cancer and its treatment have been a topic of increasing investigation over the
past ∼30 years. Recent studies have focused on better understanding the neural correlates of these
effects, with an emphasis on post-chemotherapy effects in breast cancer patients. Structural MRI
studies have utilized both automated and manual approaches to quantify gray and white matter
characteristics (e.g., regional volume and density) in breast cancer patients treated with
chemotherapy relative to patients who did not receive chemotherapy and/or healthy controls.
While most work to date has been retrospective, a small number of baseline (pre-systemic therapy)
and prospective longitudinal studies have been conducted. Data have consistently shown lower
gray and white matter volume and density in patients treated with chemotherapy, particularly in
frontal and temporal brain regions. Host factors and/or the cancer disease process and other
therapies (e.g., antiestrogen treatment) also seem likely to contribute to the observed differences,
though the relative contributions of these effects have not yet been investigated in detail. These
structural abnormalities have been shown to relate to subjective and objective cognitive
functioning, as well as to biological factors that may help to elucidate the underlying
mechanism(s). This review examines the currently available published observations and discusses
the major themes and promising directions for future studies.
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Introduction
As the literature demonstrating cognitive sequelae of cancer and its treatments has become
more established, a growing body of research has utilized advanced neuroimaging
techniques to examine the underlying neural mechanisms of these effects, particularly
cognitive symptoms attributed to systemic chemotherapy. Other papers in this special issue
review the findings from functional MRI (fMRI; de Ruiter and Schagen 2013) and diffusion
tensor imaging (DTI; Deprez et al. 2013), and integrate the structural and functional
literature (Pomykala et al. 2013). Here we review the current structural MRI literature
examining cancer- and treatment-related alterations in brain morphology.
Studies examining brain structure typically implement analytic approaches designed to
segment the brain into specific structures (e.g., hippocampus) or tissue compartments (e.g.,
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gray or white matter, GM and WM respectively) of interest, via either manual tracing or
automated segmentation or parcellation approaches. Manual tracing techniques typically
utilize a standard, manualized approach to delineating regions of interest (ROIs), which
most commonly encompass a particular brain structure. Such protocols rely on anatomic
landmarks and conventional boundaries to define the ROI, and tracings must meet a defined
level of inter-and intra-rater reliability. These methods can be extremely precise for
particular ROIs in a given individual, but have the drawback of being time- and labor-
intensive. More recent studies tend to rely on automated or semi-automated approaches for
delineating ROIs. For example, image processing software packages such as FreeSurfer
(Dale et al. 1999; Fischl et al. 1999) are available to automatically parcellate MRI data into
specific ROIs (e.g., brain structures or lobar regions of interest) and extract volumetric and
cortical thickness values.
Voxel-based morphometry (VBM) is another commonly used method for quantitative
evaluation of structural differences on a voxel-by-voxel basis throughout the entire brain
(Ashburner and Friston 2000, 2001; Good et al. 2001). As VBM is used in a number of the
studies discussed in this review, a brief description of the method is provided, along with
some important considerations for its use. Unlike morphological methods that involve
manual segmentation of selected structures, VBM is a fully automated procedure for
examining tissue integrity, which allows quantification of regional volume and density of
brain tissue compartments. VBM implements statistical parametric mapping procedures to
assess tissue-specific intensity values across every voxel in the brain relative to a user-
defined statistical threshold, providing an unbiased, comprehensive, and highly reliable
assessment of tissue characteristics sensitive to local differences. As part of VBM
processing, the user can elect to mathematically “modulate” the data by multiplying voxel
values by the determinant of the Jacobian matrix, to account for the effects of spatial
normalization and preserve the original relative volumes of brain regions. However, a recent
validation study suggests that modulation significantly reduces the ability of VBM to detect
mesoscopic (i.e., between microscopic and macroscopic) differences (Radua et al. 2013).
Without modulation, relative tissue concentration is preserved. Studies using modulated data
therefore generally refer to differences in regional brain volume, while those using
unmodulated data refer to differences in regional brain density or concentration (Mechelli et
al. 2005). Another consideration when using VBM is whether or how to model “global”
differences between groups. For example, total intracranial volume can be included in
analyses as a covariate of no interest to control for the potential confound of overall brain
size when examining regional differences in tissue volume or density. Alternatively, global
or local scaling techniques can be utilized to remove overall between-group differences.
These approaches can result in significant alterations in data, such that differing findings
among VBM studies may be attributable in part to such variations in processing and analytic
approaches (Mechelli et al. 2005; Peelle et al. 2012).
This review will focus on studies of patients with breast cancer, where the majority of
relevant work has been conducted to date (see Table 1 for a summary of articles reviewed
here). As noted in Deprez et al. in this issue (Deprez et al. 2013), for the purposes of this
special issue we are most interested in the effects of treatments for non-CNS cancers that are
not directly targeting the CNS. We therefore will not review the growing literature
documenting GM and WM abnormalities and their cognitive correlates in individuals during
and after intrathecal chemotherapy treatment (often with high-dose methotrexate) for acute
lymphoblastic leukemia (ALL; e.g., Carey et al. 2008; Ciesielski et al. 1999; Glass et al.
2006; Kesler et al. 2010; Lesnik et al. 1998; Reddick et al. 2006). Similarly, while there are
a number of reports of acute or reversible leukoencephalopathy as a neurologic complication
linked to chemotherapy in various cancer populations, these are typically qualitative or
descriptive in nature, rather than based on statistical comparisons, and so will not be covered
McDonald and Saykin Page 2













here. Finally, as the focus of this review is on the effects of cancer and its treatments on
MRI measures of brain structure, we will not review the small literature examining brain
structure in relation to psychiatric symptomatology in breast cancer patients, but not as
related to cancer or its treatment (Hakamata et al. 2007; Hara et al. 2008; Inagaki et al. 2004;
Matsuoka et al. 2006; Matsuoka et al. 2003; Nakano et al. 2002; Yoshikawa et al. 2006).
However, the demonstration of a potential relationship between symptoms of depressive and
anxiety disorders and volume of specific brain structures in cancer patients highlights the
need to examine these and other psychosocial factors and patient-specific covariates (see
discussion of Scherling et al. 2012 below) when conducting this type of research, to explore
potential explanatory factors when differences are found.
Examination of brain structure in breast cancer survivors treated with
chemotherapy
White matter change after high-dose chemotherapy with bone marrow support
In some of the earliest systematic work in this area, Stemmer, Brown, and colleagues
published a series of papers examining WM changes after high-dose chemotherapy for
breast cancer (Brown et al. 1995; Brown et al. 1998; Stemmer et al. 1994). This group
(Stemmer et al. 1994) initially reported on 13 high-risk breast cancer patients (stage II-IV
disease) studied with MRI after high-dose cyclophosphamide, cisplatin, carmustine, and
autologous bone marrow support. Eight patients had a single post-treatment MRI scan, while
five had serial studies. Five patients had scans prior to bone marrow support chemotherapy
(though all had previously received standard-dose systemic chemotherapy and/or induction
chemotherapy in preparation for transplant); no abnormalities were apparent on these scans.
Based on neuroradiological ratings, four patients had severe WM changes post-transplant,
four had moderate changes, and one had mild changes, while four did not demonstrate
abnormality. Changes seemed more frequent and severe five or more months post-
transplant. However, the authors did not find a relationship between WM changes and
neurological status. In a subsequent paper, this group (Brown et al. 1995) compared MRI
and magnetic resonance spectroscopy (MRS) findings in 13 similar patients (it was not clear
whether this group of patients overlapped with those in the previous report) relative to 13
matched controls, including semi-automated measurement of the degree of WM
abnormality. Scans were conducted on average 12 months after treatment completion, and
showed WM abnormalities ranging from 1 to 153 cm3 (mean 49±50 cm3). MRS measures,
including N-acetyl aspartate (NAA)/creatine (Cr) and NAA/choline (Cho) ratios, were not
abnormal relative to controls despite these structural differences, nor was there a clear
relationship between degree of WM abnormality and neurological status, though about half
of the patients experienced some post-treatment neurological complication. To clarify the
time course of these WM changes prospectively, Brown et al. (Brown et al. 1998) used
serial MRI and MRS to follow eight stage II-IV breast cancer patients over the course of
treatment, with baseline scans planned prior to induction chemotherapy (though for some
patients after standard-dose chemotherapy), after induction chemotherapy but prior to high-
dose chemotherapy and transplant, and at 1, 3, 6, 9, and 12 months after transplant with the
same regimen described above. MRI appeared normal in all patients at baseline, and in all
six patients for whom scans were available after induction chemotherapy. WM changes were
apparent in one of these patients two months post-treatment. At three months post-transplant
and later, three of four patients remaining in the study showed an increasing volume of WM
changes that stabilized in the 6- to 12-month post-treatment phase, consistent with this
group's earlier finding of development of WM abnormalities in the months post-treatment.
The highest volumes of abnormal WM for these patients were 73, 151, and 166 cm3. Despite
these WM abnormalities, few neurochemical changes were detected by MRS, although
NAA/Cr ratios suggested a transient treatment-related decrease, potentially suggestive of
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temporary neuronal dysfunction which subsequently normalizes. Again there was no clear
relationship to clinical status; while transient neurological abnormalities were noted, no
patient showed persistent CNS symptoms. Overall, this group of studies suggests significant
WM abnormalities detectable within a few months of completion of high-dose systemic
chemotherapy and bone marrow transplant. However, the clinical significance of these
findings is unclear, given the lack of a consistent relationship with neurological status. These
investigators studied patients with more advanced disease who received more aggressive
treatment than many of the studies discussed below. However, their findings demonstrate
significant structural brain changes that appear attributable to chemotherapy, laying a
foundation for subsequent work in this area.
Retrospective studies of gray and white matter in breast cancer survivors
In the first published study utilizing VBM to examine brain GM and WM differences in
patients after cancer chemotherapy, Saykin and colleagues (Saykin et al. 2003) studied 12
patients treated with chemotherapy (10 breast cancer, two lymphoma) and 12 healthy
demographically matched control participants. Patients were all greater than five years post
cancer diagnosis. Widespread abnormalities in neocortical GM and cortical and subcortical
WM volume were found in patients relative to controls, while no regions were apparent
where patients showed greater tissue volume than controls. This finding of both GM and
WM abnormalities in patients several years post cancer treatment extended the prior work
by documenting that these differences can be observed in patients with less aggressive
disease who were treated with standard-dose chemotherapy, and presented evidence that
such abnormalities appear to persist over time post-treatment.
Inagaki et al. (Inagaki et al. 2007) subsequently used VBM to compare patients who had
been treated with chemotherapy to those who had not and to a healthy control group. At an
average of four months post-treatment chemotherapy-treated patients showed lower GM
volume in the right middle and superior frontal and parahippocampal gyri and lower WM
volume in the bilateral middle frontal gyri, left precuneus and parahippocampal gyrus, and
right cingulate gyrus relative to those not receiving chemotherapy. Correlational analyses
demonstrated significant positive relationships between superior frontal and
parahippocampal GM and precuneus WM volumes and indices of attention/concentration
and/or visual memory from the Wechsler Memory Scale, Revised (WMS-R) in the
chemotherapy-treated group. At about three years post-treatment no differences were found
between the two cancer groups in samples that partially overlapped with the four-month
post-treatment analysis. When all cancer patients were compared to healthy controls no
significant volume differences were apparent at either time point, though the two cancer
groups were not separately compared to the control group. The lack of significant
differences between patients who did and did not receive chemotherapy at the three-year
time point was consistent with prior work by this group, (Yoshikawa et al. 2005, discussed
further below), in which they found no between-group differences in hippocampal volumes
in patients greater than three years after treatment completion. However, these findings
stand in contrast to other work discussed in this review demonstrating significant structural
abnormalities many years after treatment completion (Conroy et al. 2013; de Ruiter et al.
2012; Kesler et al. 2013; Koppelmans et al. 2012b). Advantages of the Inagaki et al. study
include large group sizes for this type of study, with 51-55 participants per group at the first
time point and 37-73 per group at the second time point, as well as integration of structural
MRI and cognitive data. As noted by the authors and in subsequent commentary, however,
methodological factors also affect interpretation of the results. As noted by Eichbaum et al.
(Eichbaum et al. 2007), groups were confounded by hormonal treatment status (significantly
more chemotherapy-treated than nonchemotherapy-treated patients received antiestrogen
treatment), and the majority of patients did not receive a currently recommended standard
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chemotherapy regimen (data were gathered prior to anthracycline regimens becoming
standard treatment). Additional analyses might also have been very informative in this
sample, including independent comparison of each cancer group with controls and
correlation of brain volume with cognitive performance across all three groups rather than
just within the chemotherapy-treated cohort.
To investigate potential factors related to brain structural differences after chemotherapy,
Conroy et al. (Conroy et al. 2013) examined the relationship of post-chemotherapy interval
(PCI) and oxidative and direct DNA damage in peripheral lymphocytes to GM density from
VBM, fMRI activation during working memory processing, cognitive performance, and
cognitive complaints in 24 chemotherapy-treated patients (on average six years post
treatment completion) relative to 23 matched healthy controls. Within the patient group PCI
was found to be positively correlated with GM density in the right frontal and temporal
lobes (Fig. 1), caudate, and precuneus, and in the left frontal lobe, cuneus, and putamen. In
the right frontal lobe (Brodmann areas 9 and 10) GM density was also positively related to
global cognitive functioning as measured by neuropsychological testing, and PCI was found
to be negatively correlated with working memory-related fMRI activation (Fig. 1). Between-
group analyses showed that patients evidenced lower GM density than controls in
distributed brain regions, including left temporal lobe and thalamus and right insula,
midbrain, and cerebellum. Mean GM density in these regions showed an inverse relationship
with oxidative DNA damage and learning and memory performance. Patients also showed
lower fMRI activation in the right precuneus and left temporal lobe, and showed poorer
memory functioning, greater cognitive complaints, and greater oxidative DNA damage than
the control group. These findings were interpreted as consistent with longitudinal data from
this group (McDonald et al. 2010; McDonald et al. 2013, discussed below) suggesting that
frontal GM gradually recovers over time following an initial chemotherapy-associated
insult, though between-group comparisons indicated that persistent differences were present
even several years post-treatment. The relationship of these GM findings to cognitive
functioning demonstrates their likely functional significance, while the association with
oxidative DNA damage offers clues toward a possible underlying biological mechanism. As
the authors noted, DNA damage in cancer patients can be linked to both disease-and
treatment-related factors, which merit further investigation.
de Ruiter et al. (de Ruiter et al. 2012) also undertook a multimodality imaging approach to
the examination of differences in brain structure and function in a group of breast cancer
survivors on average 9.5 years post-chemotherapy (N=17) relative to breast cancer patients
not treated with chemotherapy (N=15). The chemotherapy-treated group consisted of high-
risk breast cancer patients treated with the same standard- and high-dose chemotherapy
regimens followed by autologous peripheral blood hematopoetic progenitor-cell
transplantation rescue and subsequent tamoxifen treatment. Of note, except for one
participant who took tamoxifen, the nonchemotherapy group in this study did not receive
antiestrogen treatment. In addition to examination of brain GM using VBM, de Ruiter et al.
included DTI, MRS, and fMRI activation during memory encoding. VBM analysis showed
lower GM volume in chemotherapy-treated patients relative to those who did not receive
chemotherapy in left occipital and lateral posterior parietal cortex and bilateral precuneus
and cerebellum. When examined relative to previously reported fMRI activation during
memory encoding (de Ruiter et al. 2011), GM volume loss in left parietal cortex colocalized
with fMRI hypoactivation in the same region (Fig. 2). DTI abnormalities relative to the
nonchemotherapy group, including greater mean and radial diffusivity, were also observed
in posterior parietal regions in chemotherapy-treated patients, adjacent to the regions in
which VBM and fMRI differences were noted. These findings point toward persistent brain
structural and functional abnormalities many years after chemotherapy (though with a more
intensive treatment regimen than is in common use today), and demonstrate the presence of
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GM and WM abnormalities that relate to differences in brain function and metabolites,
illustrating potential underlying neural mechanisms for cognitive symptoms after cancer
treatment.
In the largest study of this kind to date, that notably included patients at the longest time
interval after chemotherapy completion, the same group (Koppelmans et al. 2012b)
examined brain structural differences in a group of 184 breast cancer survivors relative to
368 age-matched women who had never had cancer from a population-based cohort study
(Hofman et al. 2009). All patients were treated with the same chemotherapy regimen
(cyclophosphamide, methotrexate, and 5-fluorouracil), had not received adjuvant
antiestrogen therapy, and completed chemotherapy on average 21 years prior to MRI
scanning. Dependent measures included total brain volume (TBV), total GM and WM
volumes, and hippocampal volume, as well as whole-brain examination of focal differences
in GM using VBM. The patient group showed significantly smaller TBV and total GM
volume relative to reference subjects, with no differences in other imaging metrics. The
relative reduction of GM in patients was found to be comparable to the effect of almost four
years of age-related GM decline. Differences in this study from others discussed here
include the use of a population-based reference sample rather than a healthy control group
for comparison, as well as adjustment of analyses for a large number of covariates
previously shown to be related to brain volume (age, education, intracranial volume, height,
blood pressure, presence of diabetes, smoking status, and symptoms of depression). As this
group had previously demonstrated cognitive impairments in this group of patients
(Koppelmans et al. 2012a), the imaging findings may be indicative of neural correlates of
these symptoms.
Given the commonly reported finding of episodic memory difficulties in breast cancer
patients after chemotherapy, studies have focused on examination of differences in
hippocampal structure as well as their relationship to memory functioning in this population.
Bergouignan et al. (Bergouignan et al. 2011) examined 16 patients after breast cancer
treatment (surgery, chemotherapy, and local radiation, four also had antiestrogen treatment,
studied 18-36 months after radiation treatment) relative to 21 matched healthy controls to
examine differences in hippocampal GM as measured by an automated segmentation
procedure and relate hippocampal integrity to autobiographical memory performance. Breast
cancer patients were found to have significantly smaller hippocampi than controls (8%
volume reduction on average), as well as poorer autobiographical memory retrieval.
Analysis of anterior versus posterior hippocampus showed that posterior hippocampus was
on average 11% smaller in cancer patients than controls, while no group differences were
apparent in anterior hippocampus. Posterior hippocampal volume was also related to
autobiographical memory performance. This finding was demonstrated in breast cancer
patients without significant psychiatric comorbidity, leading the authors to infer that the
observed hippocampal and memory differences were likely attributable to the experience of
breast cancer (i.e., cancer and its treatment), rather than to any associated psychiatric
symptomatology. The authors also noted that volume reduction specific to posterior
hippocampus has previously been shown in stress-related psychiatric disorders (e.g.,
depression, anxiety, posttraumatic stress disorder). In their own sample, preliminary
analyses also suggested a relationship between distressing memories, posterior hippocampal
volume, and autobiographical memory. As this study was retrospective and did not include
patients who did not receive chemotherapy, the hippocampal and memory differences
cannot be conclusively attributed to chemotherapy, though such findings are consistent with
those observed prospectively by other groups and specifically attributed to chemotherapy
(see discussion of McDonald et al. 2010; McDonald et al. 2013 below).
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Kesler et al. (Kesler et al. 2013) also examined hippocampal volume in chemotherapy-
treated breast cancer survivors (N=42, on average nearly five years post-treatment) relative
to matched healthy controls (N=35), and looked at the relationship to memory functioning
and serum cytokine levels, to assess the potential relationship of inflammatory processes to
brain structure and function after chemotherapy. Patients showed significantly lower left
hippocampal volume relative to controls, with a trend for lower right hippocampal volume.
Patients also showed lower objective and subjective memory than controls. In those for
whom cytokine data were available interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα)
were significantly elevated in patients relative to controls. Levels of other cytokines did not
show between-group differences. Across groups left hippocampal volume was associated
with verbal memory performance and cytokine levels. In patients lower left hippocampal
volume was associated with higher levels of TNFα and lower levels of IL-6, with a
significant interaction between these, which the authors interpreted as suggestive of a
modulatory effect of IL-6 on TNFα. Older age was associated with higher levels of both
IL-6 and TNFα, and shorter time since treatment was also associated with higher TNFα
levels. Hippocampal volume was not associated with time since treatment, suggesting that
volume loss may remain stable over time. In controls left hippocampal volume was not
significantly associated with cytokine levels, though stronger verbal memory performance
was associated with lower TNFα levels and higher left hippocampal volume. Findings were
not accounted for by levels of mood symptoms or other host, disease or treatment variables
(e.g., menopausal status, tamoxifen or radiation treatment, disease stage). Based on prior
literature, the authors proposed that chemotherapeutic agents may show varying levels of
neurotoxicity and/or may differentially affect cytokine expression, which has been linked to
hippocampal damage in animal studies. Their findings therefore offer clues to potential
mechanisms underlying chemotherapy-related changes in brain structure and function.
While all the studies described above found significant reductions in brain GM and/or WM
in chemotherapy-treated patients relative to control groups, it should be noted that one study
has failed to find such differences. Yoshikawa et al. (Yoshikawa et al. 2005) studied 44
breast cancer patients who had received chemotherapy compared to 31 who had not. Thirty-
one patients in the chemotherapy group had also received tamoxifen (and may still have
been taking it, though this was unclear), while none of the patients in the comparison group
took this medication. Patients were on average 3.5 years post chemotherapy completion. The
hippocampi were traced manually, and participants also completed subtests of the WMS-R.
While chemotherapy-treated patients showed poorer scores on attention/concentration
measures, there were no between-group differences in hippocampal volume or memory
scores. This study stands in contrast to the literature discussed above showing lower GM in
breast cancer patients treated with chemotherapy, as well as to findings of smaller
hippocampal volume in patients treated with tamoxifen but not chemotherapy (see
discussion of Eberling et al. 2004 below).
In an alternative approach to examination of differences in brain volume, Hosseini et al.
(Hosseini et al. 2012) utilized graph theoretical analysis to examine differences in GM
networks between chemotherapy-treated breast cancer patients (N=37, on average 4.5 years
post-treatment) and matched healthy controls (N=38). In brief, this approach uses
computational methods to examine correlational relationships between data points, in this
case between regional brain GM volumes. Characteristics of these relationships help to
elucidate brain organization, and have previously been described in terms of the nature and
strength of connections between brain regions, using terminology related to the relative
“small-world” properties of brain networks, including factors such as the number and length
of regional connections (Bassett and Bullmore 2006; Petrella 2011; Sporns et al. 2004).
Arguing that prior studies had shown a diffuse pattern of brain structural abnormalities after
breast cancer chemotherapy suggestive of effects on large-scale brain networks, these
McDonald and Saykin Page 7













authors examined GM network connectivity across a range of network densities, and found
that overall network correlation strength was significantly lower in patients than controls.
While networks in both groups showed characteristics of small-worldness, patients showed
lower clustering coefficient and small-world index, indicative of relative reduction in small-
world properties, though the overall difference in small-worldness was at trend level of
significance (p=0.08). Examination of regional network measures showed reduced
interactivity (i.e., nodal betweenness/degree) of frontotemporal regions in patients relative to
controls, with higher values in more posterior regions (parieto-occipital) as well as anterior
cingulate and left thalamus. A smaller number of network hubs was also found in the patient
group relative to controls (three versus six hubs), with hubs in the patient group primarily in
parietal and cingulate regions while those of controls were largely in frontotemporal regions.
The authors interpret these findings as indicative of lower regional connectivity as well as
global network organization and integration in breast cancer patients after chemotherapy. In
particular, they describe the differences observed in frontotemporal regions as consistent
with prior literature noting abnormalities in GM volume and density in these areas, and
hypothesize that these network differences may be related to deficits noted in related
cognitive domains (i.e., executive functions and memory) in breast cancer patients after
treatment. Unfortunately this hypothesis could not be directly tested in this dataset as the
network measures extracted are at the group rather than the individual level. Although
highly novel, this study does not appear to have included correction for multiple
comparisons. While this is an issue common to many neuroimaging studies, given the
methodology used here such correction might be of particular utility, given the large number
of brain regions tested for significant relationships. Overall, however, Hosseini et al.
interpret their findings as suggestive of reduced robustness and efficiency of network
organization after chemotherapy. This demonstration of abnormal interconnectivity in
distributed brain regions, particularly those which have been identified in other work as
showing structural and functional abnormalities related to cancer and treatment (e.g.,
frontotemporal circuitry), offers further support for the hypothesis that alterations in the
structural integrity of these regions may underlie the cognitive symptoms observed in this
population.
Prospective and baseline studies of brain structural alterations related to
breast cancer and treatment
Prospective longitudinal examination of gray matter changes
The cross-sectional studies discussed above focused on analysis of residual structural
abnormality in the brains of patients successfully treated for breast cancer at varying
intervals post-treatment. Without baseline data, however, it is impossible to know with
certainty how much these differences are attributable to cancer treatments, including
chemotherapy, versus potential effects of the cancer disease process itself or other factors. A
small number of prospective, longitudinal studies have begun to address this question. In the
first such study, McDonald et al. (McDonald et al. 2010) compared women treated with
chemotherapy for breast cancer (N=17), breast cancer patients who did not receive
chemotherapy (N=12), and matched healthy controls (N=18). Participants completed MRI
scans at three time points: the baseline visit was conducted after surgery but prior to
adjuvant treatment (radiation, chemotherapy, or antiestrogen treatment), a second visit was
scheduled about one month after chemotherapy completion (or yoked intervals for the other
two groups), and a final visit was completed one year after the second scan. VBM was used
to compare GM density between groups and over time. No between-group differences in
GM were seen at baseline, and within-group analyses of controls and patients who did not
receive chemotherapy did not show any regions of GM decline over time. One month post-
treatment, however, the chemotherapy-treated group showed significantly reduced GM
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density compared to baseline in bilateral frontal, cerebellar, and medial temporal regions,
including hippocampus, and right thalamus (Fig. 3). Group-by-time interaction analyses
demonstrated that chemotherapy-treated patients showed significant reductions in bilateral
middle frontal and right cerebellar GM density relative to controls from baseline to one
month post-treatment, while patients who did not receive chemotherapy showed decreased
GM density in the right cerebellum relative to controls. Further longitudinal analyses
demonstrated that some of the regions where GM density decreases were observed in the
chemotherapy-treated group showed recovery to baseline values one year later, while other
regions showed persistently diminished GM density over time. Covariate analyses
demonstrated that these reductions in GM density were not attributable to time since cancer
surgery, disease stage, psychiatric symptoms, psychotropic medication use, or length of time
on antiestrogen treatment. In subsequent work this group (McDonald et al. 2012) reported
alterations in working memory-related fMRI activation that overlapped with these GM
changes in frontal regions, demonstrating potential functional significance to these structural
alterations. These prospective study findings (McDonald et al. 2010) confirmed those of
prior retrospective work, and suggest that the observed reductions in GM density were likely
primarily attributable to chemotherapy rather than other cancer- or host-related factors.
However, the finding of milder GM changes over time in patients not treated with
chemotherapy relative to controls indicates that the potential effects of other cancer
treatments must also be investigated.
This group subsequently replicated these findings of decreased frontal GM density using
VBM in an independent, larger, more heterogeneous cohort of 27 breast cancer patients who
received chemotherapy, 28 who did not, and 24 matched controls (McDonald et al. 2013).
Participants were studied at the same intervals as described above, though analyses included
only the first two study visits, as the study was ongoing and only partial data was available
for the final study visit at the time of that report. In this second cohort patients who did not
receive chemotherapy showed lower GM density in the left cingulate gyrus at baseline
relative to controls. This finding was of uncertain significance; it seemed unlikely to be
related to cancer per se, as no such difference was seen between chemotherapy-treated
patients and controls. In addition, this region did not evidence significant change over time
in within-group or interaction analyses. Consistent with the prior study (McDonald et al.
2010), interaction analyses showed that patients treated with chemotherapy had decreased
GM density in the left middle frontal gyrus at one month post-treatment relative to controls.
Within-group analyses showed decreased left middle and superior frontal GM density in the
chemotherapy-treated group at one month post-treatment relative to baseline. Such changes
were again not evident in patients who did not receive chemotherapy or controls. Within the
chemotherapy-treated group GM density in the left middle frontal gyrus was found to
correlate with self-reported difficulties in executive functions as measured by the Behavioral
Rating Inventory of Executive Function-Adult Version (BRIEF-A), with reduced GM
density at one month post-treatment showing an association with greater complaints in terms
of ability to initiate problem-solving or activity. In order to evaluate possible risk factors for
chemotherapy-related changes GM density and BRIEF-A scores were compared between
patients with and without the apolipoprotein (APOE) ε4 allele, a known risk factor for
cognitive changes. No between-group differences were found based on APOE ε4 status,
though it was noted that a relatively higher percentage of chemotherapy-treated patients
carried this allele. These findings provided confirmatory evidence that the observed
reductions in GM density were most likely attributable to chemotherapy treatment, as such
changes were not observed in patients who did not receive chemotherapy or controls. In
addition, the finding of a relationship between frontal GM density and self-reported
executive functioning was consistent with a prior fMRI study (Kesler et al. 2011) reporting a
correlation between brain activation during an executive functioning task and BRIEF-A
ratings in the same frontal regions (Brodmann areas 8, 10, and 46). Likewise, the GM
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changes observed are consistent not only with these researchers' other studies (Conroy et al.
2013; McDonald et al. 2010, 2012), but with those of other groups demonstrating structural
and functional brain abnormalities prior to adjuvant treatment (Scherling et al. 2011;
Scherling et al. 2012) and post-treatment (de Ruiter et al. 2011; Kesler et al. 2009; Kesler et
al. 2011; Silverman et al. 2007).
Pre-treatment examination of gray and white matter differences
One other published paper to date has examined GM and WM prior to planned
chemotherapy for breast cancer (Scherling et al. 2012). These authors studied 23 patients
prior to initiation of chemotherapy compared to 23 demographically matched healthy
controls. Patients were studied post-surgery but prior to adjuvant treatment, and VBM was
conducted on both GM and WM, using whole-brain and ROI-based analyses. These authors
were particularly interested in examining the potential effects of possible confounding
variables on group differences in brain structure, including demographic, psychological, and
biological factors such as time since surgery, diurnal cortisol levels, estrogen, symptoms of
depression or anxiety, and estimated intellectual ability. Of note, while patient and control
groups did not differ in terms of measured cognitive functioning, estrogen, or cortisol levels,
patients did show significantly higher mean scores on measures of depression and anxiety
symptoms, though group means remained within the nonclinical range for these scales.
Comparisons of GM values revealed no between-group differences for either whole-brain or
ROI analyses, and inclusion of covariates did not significantly modify these results. For
WM, no significant between-group differences were apparent in whole-brain analyses,
though ROI analyses showed smaller WM volumes in patients than controls in bilateral
inferior frontal, left pre- and post-central, insula, striatum, inferior parietal, precuneus, and
corpus callosum, and right supramarginal and middle temporal regions. Interestingly,
addition of some covariates to the analyses (depression and anxiety symptoms, time since
surgery) resulted in significantly higher WM values in patients than controls in right
parahippocampal and left occipital ROIs, while inclusion of other covariates continued to
demonstrate lower WM in patients relative to controls in ROI-based analyses, but altered
which regions demonstrated significant differences. For both GM and WM, regression
analyses showed relationships between regional brain volume and the variables of interest,
including symptoms of depression and anxiety, estimated intellect, time since surgery, and
cortisol levels. These relationships differed depending on whether the whole sample or
individual groups (breast cancer patients or controls) were examined, and varied in
directionality depending on the analysis. For example, level of depression symptoms was
associated with larger or smaller GM volumes, depending on brain region and group
examined. Results from this study were generally consistent with the baseline findings of the
longitudinal studies described above (McDonald et al. 2010; McDonald et al. 2013), which
showed little to no pre-treatment difference in GM between breast cancer patients and
healthy controls. Scherling et al. did demonstrate pre-chemotherapy abnormalities in WM in
patients relative to controls; while these were not apparent in whole-brain analyses, they
were evident when specific ROIs were examined. As the authors note, these findings can
therefore be thought of as reflecting more subtle differences in brain structure than those
typically detected by whole-brain analytic approaches.
Potential effects of disease process and other treatments
It is also important to consider the potential role of the cancer disease process itself and
other treatments (e.g., surgery, local radiation, antiestrogen treatment, etc.) in the brain
structural abnormalities observed in cancer patients. While the studies noted above have
found only limited structural differences prior to adjuvant treatment, post-chemotherapy
findings are to some degree confounded with additional treatments which have also been
implemented. In a study focusing on the role of estrogen in brain structure and function in
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postmenopausal women, Eberling et al. (Eberling et al. 2004) examined healthy women who
either were (ERT+, N=15) or were not (ERT-, N=15) taking estrogen and breast cancer
patients taking tamoxifen (TAM, N=10), five of whom had received radiation, but none of
whom had received chemotherapy. Participants underwent FDG PET, structural MRI with
manual segmentation of the hippocampus, and cognitive evaluation. The authors
hypothesized that estrogen would have a neuroprotective effect in this context, such that
estrogen use would be related to greater hippocampal volume, while tamoxifen use would be
associated with lower volume (and lower glucose metabolism on PET). Consistent with this
hypothesis, after removal of one outlier from the TAM group, hippocampal volumes were
significantly smaller in the TAM group relative to ERT+ bilaterally, with ERT-participants
showing intermediate volumes. While the TAM group also showed significantly poorer
performance than the other two groups on a semantic memory task, task performance was
not directly related to hippocampal volume. There was no relationship of hippocampal
volume to hippocampal glucose metabolism, nor were group differences in hippocampal
glucose metabolism observed, though significant differences in frontal glucose metabolism
were found between all groups (i.e., ERT+>ERT-, ERT+>TAM, ERT->TAM). Given the
study design, the contribution of cancer versus its treatments to the observed findings cannot
be separated, but these results suggest that the potential effects of cancer itself or of other
cancer treatments must be carefully considered when studying presumed effects of
chemotherapy on brain structure.
Discussion
Examination of brain structural alterations related to breast cancer and its treatment has
progressed dramatically over the past two decades. Initial studies demonstrating overt WM
abnormalities (Brown et al. 1995; Brown et al. 1998; Stemmer et al. 1994) laid a foundation
for more sophisticated analytic approaches using advanced image analysis techniques. Since
this earliest work, several studies (Bergouignan et al. 2011; Conroy et al. 2013; Inagaki et al.
2007; Kesler et al. 2013; Koppelmans et al. 2012b; de Ruiter et al. 2012; Saykin et al. 2003)
have consistently demonstrated lower volumes of GM and WM in chemotherapy-treated
breast cancer survivors relative to comparison groups (breast cancer patients not treated with
chemotherapy and/or healthy controls) using both manual and automated analytic
techniques, with only one published study failing to document such differences (Yoshikawa
et al. 2005). However, it should also be noted that investigators may not seek to publish
negative findings, leading to a bias in the literature toward studies demonstrating significant
between-group differences. Abnormal GM connectivity characteristics have also been
demonstrated in regions overlapping with those showing volumetric differences (Hosseini et
al. 2012). These retrospective studies have examined patients from several months to >20
years post-treatment, and have found volumetric differences in diffuse brain regions, though
changes in frontal and temporal regions, including medial temporal structures such as the
hippocampus, have been among the most consistent findings across studies. The limited data
examining patients at baseline (post-surgery but prior to adjuvant treatment) have generally
not demonstrated significant abnormalities in GM between breast cancer patients and
controls (though baseline differences in the left cingulate were noted in one study
(McDonald et al. 2013)). Reduced WM at baseline has likewise been reported using some
analytic approaches but not others (Scherling et al. 2012). Prospective longitudinal
investigations (McDonald et al. 2010; McDonald et al. 2013) have shown significant
reductions in GM after chemotherapy relative to baseline, again prominently in frontal and
temporal lobe regions, which appear to demonstrate partial but not complete recovery over
time, consistent with the residual differences noted in the retrospective literature. Limited
evidence suggests that antiestrogen treatment may also contribute to these alterations in
brain structure (Eberling et al. 2004; McDonald et al. 2010), though the effects of
chemotherapy appear much more pronounced.
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These reductions in brain volumes in chemotherapy-treated patients, particularly in the
frontal lobes (e.g., Brodmann areas 8, 9, and 10), have been demonstrated to correlate with
objective and subjective cognitive functioning, subject-specific demographic and treatment
variables (e.g., PCI), and/or biological factors which may point toward underlying etiology,
including oxidative DNA damage and cytokine and brain metabolite levels (Bergouignan et
al. 2011; Conroy et al. 2013; Inagaki et al. 2007; Kesler et al. 2013; McDonald et al. 2013;
de Ruiter et al. 2012). Regional differences in brain structure have also been demonstrated to
correlate or colocalize with brain activation as measured by fMRI (Conroy et al. 2013;
McDonald et al. 2012; Michiel B. de Ruiter et al. 2012), further demonstrating the
functional significance of these structural abnormalities. Frontal abnormalities have also
been demonstrated in the limited available DTI literature in this population, and have
demonstrated correlations with cognition in some work (Deprez et al. 2012; Deprez et al.
2011; de Ruiter et al. 2012). This indicates a potential WM correlate for the GM changes
discussed here, as well as further evidence for a neural substrate of cancer- and treatment-
related functional changes. While baseline comparisons show some structural differences
potentially attributable to host factors and/or the cancer disease process, much more
dramatic group abnormalities are evident post-treatment, particularly after systemic
chemotherapy. Taken in combination, these data offer consistent support for reductions in
brain gray and white matter after cancer chemotherapy, even therapy which does not target
the CNS, in a non-CNS cancer. Furthermore, where focal findings have been noted, the
frontal and temporal brain regions most typically affected are also those which subserve
cognitive functions commonly reported to show cancer- and treatment-related effects,
including executive functions and episodic memory.
The consistency of brain regions found to demonstrate reductions in GM and WM density
and/or volume after breast cancer chemotherapy is noteworthy, with frontal and temporal
regions repeatedly demonstrating such abnormalities in studies with differing comparison
groups (i.e., patients treated without chemotherapy or healthy controls) and at different
magnet field strengths (i.e., 1.5 versus 3 Tesla). While such regional differences have been
most prominent in several studies, more diffuse changes are noted in others. As cancer
treatments, including chemotherapy, can be conceptualized as a diffuse insult, treatments
administered systemically might be predicted to lead to diffuse rather than focal brain
effects. The focal findings described above in may be related to both methodological and
biological factors. Imaging analyses utilize different approaches to selection of statistical
thresholds. It is therefore the case that while focal changes are noted at a particular level of
statistical rigor, more diffuse findings may be observed at a more lenient threshold.
Therefore, more varying patterns of brain changes related to cancer and its treatment may be
found depending upon the analytic approach taken. In addition, as noted above, variations in
image preprocessing steps (e.g., use of modulated or unmodulated VBM data) can directly
impact the ability to detect regional group differences. However, it also seems plausible that
frontal and temporal brain regions may be more vulnerable to cancer- and treatment-related
effects. As noted above, an extensive literature has documented cognitive effects in
neuropsychological functions primarily subserved by frontotemporal systems, but has not
typically found global cognitive impairment in this population. As discussed further below,
the link between cancer and aging has prompted increased examination of commonalities
between cognitive and brain changes related to cancer and its treatment and those related to
the aging process, including both “normal” age-related cognitive change and pathological
processes such as Alzheimer's disease and its precursors. For example, frontal regions have
been demonstrated to show age-related GM and WM changes prior to more posterior
regions (Gunning-Dixon et al. 2009; Peelle et al. 2012), and atrophy of medial temporal
regions is among the earliest structural changes apparent in Alzheimer's disease, and one of
the best predictors of conversion from prodromal to more advanced disease (Risacher et al.
2009; Risacher et al. 2010). Of note, in cancer survivors those studies examining older
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patients (who are also those further out from cancer treatment) have found more diffuse GM
changes, rather than focal differences (e.g., Koppelmans et al. 2012b). This prompts the
question of whether more regional changes may be present in younger individuals or those
in earlier stages relative to cancer diagnosis and treatment, with perhaps more diffuse effects
becoming apparent over time as a result of an interaction between cancer- and treatment-
related effects and the aging process. The biological mechanisms underlying these changes
are under active investigation, and proposed etiologies in cancer populations have included
chemotherapy-induced DNA damage (directly or through increases in oxidative stress),
individual variation in genes related to neural repair and/or plasticity, and chemotherapy-
induced hormonal changes (Ahles and Saykin 2007). The studies discussed above offer
preliminary support for some of these hypothesized etiologies, particularly in terms of
oxidative DNA damage and inflammatory process involvement.
As mentioned above, multiple lines of evidence also suggest that there may be an interaction
between cognitive and brain changes related to cancer and its treatment and cognitive
disorders of aging, including Alzheimer's disease and its precursors. Convergent data from
cognitive, imaging, genetic, and other biomarker studies suggest that older breast cancer
patients may be more vulnerable to structural and functional brain changes after
chemotherapy, and that these abnormalities may be related to alterations in immune
functioning after breast cancer treatment (Mandelblatt et al. in press). As discussed by Ahles
et al. (Ahles et al. 2012), while the mechanisms leading to increased cancer risk with age are
incompletely understood, both the aging process and chemotherapy treatment are associated
with biological factors such as DNA damage, oxidative stress, inflammation, and decreased
telomere length. As outlined by these authors, the commonality of underlying biological
processes related to cancer- and treatment-related cognitive changes and cognitive disorders
of aging suggests the possibility that cancer treatments may accelerate the aging process in
vulnerable individuals, either by shifting the trajectory of cognitive dysfunction to an earlier
point in the lifespan, or accelerating this trajectory altogether (Ahles et al. 2012). As
different mechanisms may contribute to this process for different individuals, and as these
potential effects are not mutually exclusive, research focusing on older patients will be
important to address these questions, as most studies to date have focused on younger breast
cancer patients (in their 40s-50s).
Some potential confounding factors will require further investigation, though treatment
patterns make this a challenge. For example, it is typically the case that patients receiving
chemotherapy have higher stage disease than those not treated with chemotherapy, while
those not receiving chemotherapy tend to skew slightly older. The issue of menopausal
status and chemotherapy-induced amenorrhea (see Conroy et al. 2013 in this issue)) is also
likely important when considering structural and functional brain changes in this population,
but may be confounded with treatment status. Likewise, it is difficult to disentangle effects
of antiestrogen treatments from those of other modalities, given current practice patterns.
While the retrospective studies described above have been critical for advancing our
understanding of post-treatment effects, additional prospective work continues to be needed
to discriminate cancer- versus treatment-related effects on brain structure and function, and
to monitor the course of these changes over time. It will also be critical to further examine
the relationship of observed changes to brain function (e.g., cognitive and behavioral
measures, fMRI and other neurophysiological markers), to assess the functional significance
of these findings. As discussed above, consideration must also be given to inclusion of
appropriate covariates, as these can significantly affect the observed findings. Given the
challenges inherent in recruiting participants to these types of studies, multicenter
collaborations will likely be the most effective way to gather enough data to meaningfully
answer mechanistic and biological questions regarding the etiology of these changes,
particularly when consideration is given to factors like genetic risk. In addition, such larger
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studies will be needed to obtain sufficiently heterogeneous samples to adequately address
the many potential risk factors of interest (e.g., socioeconomic and other medical and mental
health variables, cognitive reserve, effect of specific chemotherapy regimens, etc.). Future
research along these lines will be able to build upon the knowledge gained to date, with the
overarching goal of elucidating biological mechanisms underlying these brain changes, in
order to advance work in the areas of effective treatment and compensatory strategies, as
well as possible approaches to prevent cancer- and treatment-related changes in brain
structure and function.
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Functional and structural overlap in the right anterior middle frontal gyrus. Gray matter
density as measured by VBM (red) was positively correlated with post-chemotherapy
interval, while working memory-related fMRI activation (blue) was negatively correlated
with post-chemotherapy interval (voxelwise p uncorrected=0.001, cluster size=10 for both
modalities; from Conroy et al. 2013).
McDonald and Saykin Page 18














Lower regional gray matter volume as measured by VBM in chemotherapy- compared to
no-chemotherapy patients overlaps with fMRI hypoactivation during a paired associates task
in left posterior parietal cortex. Right posterior parietal cortex shows hypoactivation but no
volume reduction. Bilateral cerebellum shows volume reduction but not task-related
activation. Color bars show range of corrected (VBM) and uncorrected (fMRI) p values
(from de Ruiter et al. 2012).
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Regional gray matter density declines as measured by VBM in chemotherapy-treated breast
cancer patients from baseline to 1 month after chemotherapy (voxelwise p
uncorrected=0.001, cluster size=1,400; from McDonald et al. 2010).
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